|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Acebutolol#Use in Specific Populations]] |
| {{Acebutolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| ====Teratogenic Effects====
| |
| | |
| Pregnancy Category B: Reproduction studies have been performed with Sectral in rats (up to 630 mg/kg/day) and rabbits (up to 135 mg/kg/day). These doses are equivalent to approximately 31.5 and 6.8 times the maximum recommended therapeutic dose in a 60-kg human, respectively. The compound was not teratogenic in either species. In the rabbit, however, doses of 135 mg/kg/day caused slight fetal growth retardation; this effect was considered to be a result of maternal toxicity, as evidenced by reduced food intake, a lowered rate of body weight gain, and mortality. Studies have also been performed in these species with diacetolol (at doses of up to 450 mg/kg/day in rabbits and up to 1800 mg/kg/day in rats). Other than a significant elevation in postimplantation loss with 450 mg/kg/day diacetolol, a level at which food consumption and body weight gain were reduced in rabbit dams and a nonstatistically significant increase in incidence of bilateral cataract in rat fetuses from dams treated with 1800 mg/kg/day diacetolol, there was no evidence of harm to the fetus. There are no adequate and well-controlled trials in pregnant women. Because animal teratology studies are not always predictive of the human response, Sectral should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
| |
| | |
| ===Nonteratogenic Effects===
| |
| | |
| Studies in humans have shown that both acebutolol and diacetolol cross the placenta. Neonates of mothers who have received acebutolol during pregnancy have reduced birth weight, decreased blood pressure, and decreased heart rate. In the newborn the elimination half-life of acebutolol was 6 to 14 hours, while the half-life of diacetolol was 24 to 30 hours for the first 24 hours after birth, followed by a half-life of 12 to 16 hours. Adequate facilities for monitoring these infants at birth should be available.
| |
| | |
| ===Labor and Delivery===
| |
| | |
| The effect of Sectral on labor and delivery in pregnant women is unknown. Studies in animals have not shown any effect of Sectral on the usual course of labor and delivery.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Acebutolol and diacetolol also appear in breast milk with a milk:plasma ratio of 7.1 and 12.2, respectively. Use in nursing mothers is not recommended.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Clinical studies of Sectral and other reported clinical experience is inadequate to determine whether there are differences in safety or effectiveness between patients above or below age 65.
| |
| | |
| Elderly subjects evidence greater bioavailability of acebutolol (see CLINICAL PHARMACOLOGY—Pharmacokinetics and Metabolism), presumably because of age-related reduction in first-pass metabolism and renal function. Therefore, it may be appropriate to start elderly patients at the low end of the dosing range
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SECTRAL (ACEBUTOLOL HYDROCHLORIDE) CAPSULE [PROMIUS PHARMA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7eee95bf-0452-4d6e-9712-33403768695a | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |